Researchers studying Merck & Co. Inc.’s cancer drug Keytruda for HIV patients who also have cancer say the immunotherapy may help displace the virus from human immune cells, offering an intriguing area of study for treatment of chronic HIV infection.
British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement to jointly develop five cancer-killing viral immunotherapies.
Waltham, Mass.-based Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck, which will license exclusive rights to Dragonfly’s TriNKET technology platform for a number of solid-tumor programs.
Chinese manufacturer Cellular Biomedicine has been enlisted to make Novartis’ $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world’s most populous country.
U.S. congressional committee members warned that Washington’s funding of the World Health Organization’s cancer research agency could be halted unless it is more open about its operations.
Authorities in China have launched an investigation after a report that hundreds of children attending a language school built near a polluted former industrial site developed health problems, including cancer, […]
